Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Targeting Endothelial Adhesion Molecule Transcription for Treatment of Inflammatory Disease: A Proof-of-Concept Study.

Ashander LM, Appukuttan B, Ma Y, Gardner-Stephen D, Smith JR.

Mediators Inflamm. 2016;2016:7945848. doi: 10.1155/2016/7945848. Epub 2016 May 16.

2.

Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C.

Nielsen MJ, Veidal SS, Karsdal MA, Ørsnes-Leeming DJ, Vainer B, Gardner SD, Hamatake R, Goodman ZD, Schuppan D, Patel K.

Liver Int. 2015 Feb;35(2):429-37. doi: 10.1111/liv.12700. Epub 2014 Oct 29.

PMID:
25308921
3.

Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C.

Patel K, Remlinger KS, Walker TG, Leitner P, Lucas JE, Gardner SD, McHutchison JG, Irving W, Guha IN.

Clin Gastroenterol Hepatol. 2014 Dec;12(12):2113-20.e1-3. doi: 10.1016/j.cgh.2014.04.037. Epub 2014 May 9.

4.

Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection.

Chiba-Falek O, Linnertz C, Guyton J, Gardner SD, Roses AD, McCarthy JJ, Patel K.

Hum Genet. 2012 Dec;131(12):1911-20. doi: 10.1007/s00439-012-1220-0. Epub 2012 Aug 17.

PMID:
22898894
5.

Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C.

Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, Thompson A, Clark PJ, Gardner SD, McHutchison JG, McCarthy JJ.

J Hepatol. 2011 Dec;55(6):1195-200. doi: 10.1016/j.jhep.2011.03.015. Epub 2011 Apr 14.

6.

Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance.

Perrillo RP, Hann HW, Schiff E, Mutimer D, Willems B, Leung N, Lee WM, Dixon S, Woessner M, Brosgart CL, Condreay LD, Gardner SD.

Hepatol Int. 2011 Jun;5(2):654-63. doi: 10.1007/s12072-010-9228-9. Epub 2011 Jan 5.

7.

A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide.

Hu DG, Gardner-Stephen D, Severi G, Gregory PA, Treloar J, Giles GG, English DR, Hopper JL, Tilley WD, Mackenzie PI.

Mol Pharmacol. 2010 Oct;78(4):714-22. doi: 10.1124/mol.110.065953. Epub 2010 Jul 13.

PMID:
20628005
8.

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, Suchindran S, Muir AJ, Guyton JR, Gardner SD, McHutchison JG, McCarthy JJ.

Hepatology. 2010 Jun;51(6):1904-11. doi: 10.1002/hep.23592.

9.

The regulation of UDP-glucuronosyltransferase genes by tissue-specific and ligand-activated transcription factors.

Mackenzie PI, Hu DG, Gardner-Stephen DA.

Drug Metab Rev. 2010 Feb;42(1):99-109. doi: 10.3109/03602530903209544.

PMID:
20070244
10.

Liver-enriched transcription factors and their role in regulating UDP glucuronosyltransferase gene expression.

Gardner-Stephen DA, Mackenzie PI.

Curr Drug Metab. 2008 Jun;9(5):439-52. Review.

PMID:
18537579
11.

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, Brosgart CL, Woessner MA, Scott SA, Gray DF, Gardner SD.

J Hepatol. 2008 May;48(5):728-35. doi: 10.1016/j.jhep.2007.12.026. Epub 2008 Feb 29.

PMID:
18329126
12.
13.
14.

The caudal-related homeodomain protein Cdx2 and hepatocyte nuclear factor 1alpha cooperatively regulate the UDP-glucuronosyltransferase 2B7 gene promoter.

Gregory PA, Gardner-Stephen DA, Rogers A, Michael MZ, Mackenzie PI.

Pharmacogenet Genomics. 2006 Jul;16(7):527-36.

PMID:
16788384
15.
16.

Human UDP-glucuronosyltransferase 1A5: identification, expression, and activity.

Finel M, Li X, Gardner-Stephen D, Bratton S, Mackenzie PI, Radominska-Pandya A.

J Pharmacol Exp Ther. 2005 Dec;315(3):1143-9. Epub 2005 Aug 24.

PMID:
16120810
17.

Polymorphic variations in the expression of the chemical detoxifying UDP glucuronosyltransferases.

Mackenzie PI, Gregory PA, Lewinsky RH, Yasmin SN, Height T, McKinnon RA, Gardner-Stephen DA.

Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):77-83. Review.

PMID:
15979674
18.

Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B.

Rizzetto M, Tassopoulos NC, Goldin RD, Esteban R, Santantonio T, Heathcote EJ, Lagget M, Taak NK, Woessner MA, Gardner SD.

J Hepatol. 2005 Feb;42(2):173-9.

PMID:
15664241
19.

Regulation of UDP glucuronosyltransferases in the gastrointestinal tract.

Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI.

Toxicol Appl Pharmacol. 2004 Sep 15;199(3):354-63. Review.

PMID:
15364550
20.

Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection.

Hom X, Little NR, Gardner SD, Jonas MM.

Pediatr Infect Dis J. 2004 May;23(5):441-5.

PMID:
15131468
21.
22.

Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid.

Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, Miners JO.

Drug Metab Dispos. 2004 Apr;32(4):413-23. Erratum in: Drug Metab Dispos. 2005 Dec;33(12):1925-6.

PMID:
15039294
23.

Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression.

Gardner-Stephen D, Heydel JM, Goyal A, Lu Y, Xie W, Lindblom T, Mackenzie P, Radominska-Pandya A.

Drug Metab Dispos. 2004 Mar;32(3):340-7.

24.

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M.

Gastroenterology. 2003 Dec;125(6):1714-22.

PMID:
14724824
25.

Cloning and characterization of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 gene promoters: differential regulation through an interior-like region.

Gregory PA, Gardner-Stephen DA, Lewinsky RH, Duncliffe KN, Mackenzie PI.

J Biol Chem. 2003 Sep 19;278(38):36107-14. Epub 2003 Jul 7.

26.

Regulation of UDP glucuronosyltransferase genes.

Mackenzie PI, Gregory PA, Gardner-Stephen DA, Lewinsky RH, Jorgensen BR, Nishiyama T, Xie W, Radominska-Pandya A.

Curr Drug Metab. 2003 Jun;4(3):249-57. Review.

PMID:
12769669
27.

A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis.

Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G, Gardner SD, Brown N, Griffiths D; United States Lamivudine Compassionate Use Study Group.

Liver Transpl. 2003 Jan;9(1):49-56.

28.

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.

Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA.

Gastroenterology. 2002 Sep;123(3):719-27.

PMID:
12198698
29.

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD.

Hepatology. 2002 Jul;36(1):186-94.

PMID:
12085364
30.

Clinical trial of lamivudine in children with chronic hepatitis B.

Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell MS, Sokal EM; International Pediatric Lamivudine Investigator Group.

N Engl J Med. 2002 May 30;346(22):1706-13. Erratum in: N Engl J Med 2002 Sep 19;347(12):955. Kelley, Deirdre [corrected to Kelly, Deirdre].

Supplemental Content

Loading ...
Support Center